XY Therapeutics ApS
CVR 41120681 · Private limited company (ApS) · Active · High risk
XY Therapeutics ApS is a Private limited company (ApS), founded on , based in Charlottenlund. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 6.5% over the next 12 months, which is 4.6 times the average for Danish companies. 5 annual reports have been published, of which 3 more than six months after the end of the financial year. The latest annual report (30 Jun 2025) shows equity of DKK -9.5m and a net result of DKK -2.1m. CEO: Martin Blomberg Jensen.
Bankruptcy risk for XY Therapeutics ApS
4.6 × the average (1.41%) · higher risk than 94% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 41120681
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (6 years)
- Address
- Rosenstandsvej 17A
2920 Charlottenlund - Municipality
- Gentofte
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 40k
- Auditor
- Grant Thornton, Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 3 of 5 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -157.2% |
| Current ratio | 193% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 4 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK 3.7m | DKK 2.7m |
| Net profit | DKK -2.1m | DKK -1.4m |
| Equity | DKK -9.5m | DKK -7.4m |
| Total assets | DKK 6.0m | DKK 4.9m |
| Cash | DKK 4.9m | – |
| Short-term debt | DKK 3.1m | – |
| Avg. employees | 1 | – |
Latest annual report: Reporting class B · auditor's statement: Erklæring om udvidet gennemgang · Grant Thornton, Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jul 2024 – 30 Jun 2025 | 199 | Late | |
| 1 Jul 2023 – 30 Jun 2024 | 184 | Late | |
| 1 Jul 2022 – 30 Jun 2023 | 186 | Late | |
| 1 Jul 2021 – 30 Jun 2022 | 131 | ||
| 28 Jan 2020 – 30 Jun 2021 | 162 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Martin Blomberg Jensen | Current | |
| Owner (100%) | Holding Fertility4U ApS | Current | |
| Auditor | Grant Thornton, Godkendt Revisionspartnerselskab | Current | |
| Founder | Holding Fertility4U ApS | Current |
The CEOs' other companies
Martin Blomberg Jensen – 2 other companies
- Holding Fertility4U ApS Active
- Myfertilityapp ApS Fusioneret
Address history (0 moves)
| Rosenstandsvej 17A, 2920 Charlottenlund |
Former names
| XY Therapeutics ApS | – now |
| Fertilitypro ApS | – |
Other companies at the same address
- Holding Fertility4U ApS Active
- Kim Kristensen Fine Wine Holding ApS Active
- Myfertilityapp ApS Fusioneret
- Pure Heart Energy ApS Active
Similar companies in Gentofte
- SNL BioSolutions ApS Hellerup
- NIVI Development A/S Hellerup
- Neo Biopharm ApS Hellerup
- G2B BioSolutions ApS Hellerup
- Beatsco2 ApS Charlottenlund
- MHJ Research ApS Hellerup
- Lophora ApS Charlottenlund
- CABA APS Charlottenlund
- Devopharma ApS Charlottenlund
- C- ApS Hellerup
- UNION therapeutics A/S Hellerup
- Aktieselskabet af 1. juni 2011 II Hellerup
Questions and answers about XY Therapeutics ApS
Has XY Therapeutics ApS gone bankrupt?
No, XY Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of XY Therapeutics ApS?
Our model estimates a bankruptcy risk of 6.5% over the next 12 months (high risk), which is 4.6 times the average for Danish companies.
Who is the CEO of XY Therapeutics ApS?
Martin Blomberg Jensen is the CEO of XY Therapeutics ApS.
Who is the auditor of XY Therapeutics ApS?
XY Therapeutics ApS most recently used Grant Thornton, Godkendt Revisionspartnerselskab.
When was XY Therapeutics ApS founded?
XY Therapeutics ApS was founded on 28 January 2020.
What is the equity of XY Therapeutics ApS?
Equity was DKK -9.5m according to the annual report for the period ending 30 June 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.